<DOC>
	<DOCNO>NCT00833326</DOCNO>
	<brief_summary>This Phase 1 study patient advanced/metastatic solid tumor receive investigational study drug ARRY-334543 docetaxel ( prophylactic growth factor support ) . Patients receive increase dos study drug combination docetaxel order achieve high dose study drug possible cause unacceptable side effect . Patients follow see side effect combination cause effectiveness combination , , treat cancer . Approximately 30 patient US enrol study .</brief_summary>
	<brief_title>A Study ARRY-334543 Docetaxel Patients With Advanced Cancer</brief_title>
	<detailed_description />
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<mesh_term>Antimitotic Agents</mesh_term>
	<mesh_term>Mitogens</mesh_term>
	<criteria>Key Histologically cytologically confirm diagnosis advanced/metastatic solid tumor suitable treatment docetaxel . Tumor recur progressed follow least one line chemotherapy , except standard care exist patient refuse standard care treatment . Eastern Cooperative Oncology Group ( ECOG ) performance status ( PS ) 0 , 1 2 . Must able take retain oral medication . Other criterion exist . Key Active concomitant malignancy . Uncontrolled symptomatic brain metastasis ( patient brain metastasis steroid , steroid dose must stable least 30 day prior study start ) . Known positive serology human immunodeficiency virus ( HIV ) , hepatitis B and/or hepatitis C. Requiring intravenous ( IV ) alimentation . Pregnancy lactation . Chemotherapy , anticancer immunotherapy , monoclonal antibody biologics within 21 day prior first dose study drug . AntiErbB1 and/or ErbB2 target therapy anticancer hormonal therapy within 14 day prior first dose study drug . History hypersensitivity intolerance docetaxel . Other criterion exist .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2012</verification_date>
</DOC>